Clinical trials recruiting for Prostate Cancer (Adenocarcinoma)

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• 68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
  NCT06612580 · Phase: Early Phase 1 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
  NCT07209878 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
  NCT07332000 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 7 locations
• A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
  NCT06906471 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: Male · 2 locations
• A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
  NCT06844383 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 8 locations
• A Study to Evaluate the Performance of Confocal Microscopy to Detect Positive Margins During Radical Prostatectomy
  NCT07541911 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
  NCT07407608 · Phase: Not specified · Ages: 18 Years to 90 Years · Sex: Male · 1 location
• Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
  NCT07219303 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer
  NCT07344844 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years and older · Sex: Male · 1 location
• Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor Lesions
  NCT06774781 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1
  NCT07552922 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
  NCT06592924 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 395 locations
• Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions
  NCT07391982 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses
  NCT07196488 · Phase: Not applicable (e.g. observational or device study) · Ages: 20 Years to 90 Years · Sex: All (male and female) · 2 locations
• EFFICACY OF INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING RARP FOR THE TREATMENT OF PROSTATE CANCER
  NCT06822036 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years to 68 Years · Sex: Male · 3 locations
• FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
  NCT06636682 · Phase: Phase 2 · Ages: No age limits stated · Sex: Male · 3 locations
• Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
  NCT06862856 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · 2 locations
• Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer
  NCT06820333 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · 1 location
• LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.
  NCT07370597 · Phase: Not specified · Ages: No age limits stated · Sex: Male · 1 location
• Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & Effectiveness
  NCT07339943 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 85 Years · Sex: Male · 1 location
• Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery
  NCT07129551 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 78 Years · Sex: Male · 2 locations
• Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
  NCT06631521 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
  NCT07182279 · Phase: Phase 1, Phase 2 · Ages: 40 Years and older · Sex: Male · 1 location
• Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer
  NCT06834152 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · 3 locations
• PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
  NCT07426055 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• PSMA PET for Surveillance After Focal Therapy
  NCT07115914 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• Personalization of External Beam Radiation Therapy in Localised Tumours
  NCT07047495 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT06801236 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 9 locations
• Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma
  NCT07316686 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
  NCT07516886 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · 1 location
• Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
  NCT06957691 · Phase: Phase 2 · Ages: 40 Years and older · Sex: Male · 1 location
• Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
  NCT06926374 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore
  NCT07617272 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• Prostatic Size Reduction Following of Leuprorelin Acetate
  NCT06184464 · Phase: Not specified · Ages: 18 Years to 95 Years · Sex: Male · 1 location
• REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)
  NCT07302451 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial
  NCT06915909 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: Male · 1 location
• Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
  NCT07179783 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Stereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins
  NCT06665932 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
  NCT07745361 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 14 locations
• Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria
  NCT07484971 · Phase: Not specified · Ages: 19 Years and older · Sex: Male · 24 locations
• The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
  NCT07038304 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer
  NCT07363382 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: Male · 1 location
• Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
  NCT06616597 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location

Related conditions

Trials recruiting for Prostate Cancer (Adenocarcinoma) often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Prostate Cancer (Adenocarcinoma) trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.